ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of ...

Kymera Therapeutics Inc (KYMR) showcases robust financial health and strategic pipeline advancements amid competitive ...

Sex releases feel-good hormones and makes you feel closer to your partner or more attuned to your body. Learn what science ...

Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that disrupts the communication between nerves and muscles. It ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA Ph: +1-203-852-6800, 800-243-6002 ...

SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

The dynamics of the eosinophilic esophagitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as APT-1011 (Ellodi Pharmaceuticals) ...